Lucie C. Kompier

FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy

Lucie C. Kompier, Irene Lurkin, Madelon N.M. van der Aa et al. · PLoS ONE · 2010 · 314 citations · Full text

Medicine, Oncology, Urology +17

Genome-wide Analysis of CpG Island Methylation in Bladder Cancer Identified TBX2, TBX3, GATA2, and ZIC4 as pTa-Specific Prognostic Markers

Raju Kandimalla, Angela A.G. van Tilborg, Lucie C. Kompier et al. · European Urology · 2012 · 106 citations

Medicine, Molecular Genetics, Oncology +17

The development of multiple bladder tumour recurrences in relation to the <i>FGFR3</i> mutation status of the primary tumour

Lucie C. Kompier, Madelon NM van der Aa, Irene Lurkin et al. · The Journal of Pathology · 2008 · 49 citations

Medicine, Oncology, Urology +10

<i>FGFR3</i> Mutation Analysis in Voided Urine Samples to Decrease Cystoscopies and Cost in Nonmuscle Invasive Bladder Cancer Surveillance: A Comparison of 3 Strategies

Kim E.M. van Kessel, Lucie C. Kompier, Esther W. de Bekker‐Grob et al. · The Journal of Urology · 2012 · 33 citations · Full text

Medicine, Oncology, Urology +7

Selection of Microsatellite Markers for Bladder Cancer Diagnosis without the Need for Corresponding Blood

Angela A.G. van Tilborg, Lucie C. Kompier, Irene Lurkin et al. · PLoS ONE · 2012 · 17 citations · Full text

Life Sciences, Genetics, Oncology +17